Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients

Table 2

RA patient’s characteristics when serum samples were collected.

Total RA patients, (42.9%)
Gender: female, (%)	51 (82.3)
Median age, years, mean ± SD	50.65 ± 13.47
Months of treatment, when blood samples were collected, median (IQR) (interval):
ADA	6 (3–9) (3–84)
ETA	30 (3–54) (3–66)
INF	15 (12–51) (6–102)
Number of performed tests, (%)
ADA	9 (14.5)
ETA	29 (46.8)
INF	24 (38.7)
RF positive, (%)	58 (93.5)
ACCP positive, (%)	26 (41.9)
Erosive disease, (%)	62 (100.0)
TJC-60, median (IQR)	4 (2–12)
SJC-60, median (IQR)	3 (1–8)
Doctor’s GDA, mm, mean ± SD	26.48 ± 17.8
Patient’s GDA, mm, median (IQR)	36.0 (13.0–56.0)
DAS28, mean ± SD	3.44 ± 1.69
SDAI, median (IQR)	12.5 (6.0–24.6)
HAQ, median (IQR)	1.0 (0.373–1.38)
ESR, mm/h, median (IQR)	15 (8–27)
CRP, mg/L, median (IQR)	2.5 (1.2–5.7)
DMARDs use, (%)	50 (80.6)
MTX use, (%)	43 (69.4)
Medium MTX dose, mg/week, mean ± SD	11.22 ± 4.38
GK use, (%)	45 (72.6)
Prednisolone equivalent dose, mg/d, mean ± SD	7.49 ± 3.35

Notes: data presented mean ± standard deviation or median and interquartile range (IQR) or number () and percent of total number of patients;
Abbreviations: RA: rheumatoid arthritis; IQR: interquartile range; SD: standard deviation, TJC-60: 60 tender joint count, SJC-60: 60 swollen joint count, GDA:global disease activity visual analogue scale (0–100 mm), RF: IgM rheumatoid factor; ACCP: cyclic citrullinated peptide antibody, DAS28: disease activity score in 28 joints; SDAI: simplified disease activity index; HAQ: Health Assessment Questionnaire, ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DMARDs: disease-modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine, leflunomide, hydrochloroquine, and azathioprine); MTX: methotrexate, and na: data is not applicable.